Clinical research on apatinib combined with Xiaoyan decoction for the treatment of non-squamous non-small cell lung cancer
10.3969/j.issn.1000-8179.2017.14.609
- VernacularTitle:阿帕替尼联合消岩汤治疗晚期非鳞非小细胞肺癌临床疗效观察
- Author:
Xiaojiang LI
;
Shan JIANG
;
Shanqi GUO
;
Honggen LIU
;
Yingjie JIA
- Keywords:
apatinib;
non-squamous non-small cell lung cancer;
Xiaoyan decoction;
VEGF
- From:
Chinese Journal of Clinical Oncology
2017;44(14):701-705
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To determine the effect of apatinib combined with Xiaoyan decoction for the treatment of non-squamous non-small cell lung cancer. Methods:Thirty-eight patients with non-squamous non-small cell lung cancer were randomly categorized into apatinib group (group A, 18 cases) and apatinib combined with Xiaoyan decoction group (group B, 20 cases). All patients did not under-go surgical treatment, radiotherapy, or chemotherapy during the study. Results:The median progression free survival (mPFS) of ad-vanced non-squamous non-small cell lung cancer patients reached up to 3 months. The mPFS, objective response rate, and disease control rate of the apatinib combined with Xiaoyan decoction group showed no significant difference and statistical significance (P>0.05). The apatinib combined with Xiaoyan decoction group was superior to the apatinib group with regard to alleviating clinical symp-toms and adverse reactions (P<0.05). Conclusion:Xiaoyan decoction combined with apatinib can improve the clinical symptoms of pa-tients and reduce the incidence of adverse reactions in the treatment of advanced non-squamous non-small cell lung cancer.
